文献速递甲状腺疾病糖尿病

极端胰岛素抵抗综合征患者的甲状腺异常

Thyroid Abnormalities in Patients With Extreme Insulin Resistance Syndromes.
PubMed 文献 · J Clin Endocrinol Metab · 2019-01-01

极端胰岛素抵抗儿童甲状腺结节患病率(16.7%)显著高于已发表儿童患病率(2%),且与美曲普汀治疗无关;INSR纯合突变者甲状腺体积增大。

要点

  • 极端胰岛素抵抗儿童甲状腺结节患病率16.7%,显著高于已发表儿童数据的2%。
  • 美曲普汀治疗与未治疗患者的甲状腺超声特征无差异。
  • INSR纯合突变者体表面积校正甲状腺体积大于杂合突变或脂肪营养不良者。

核心结论

  • 极端胰岛素抵抗儿童甲状腺结节患病率高,且与美曲普汀治疗无关。
  • INSR纯合突变患者甲状腺肿大可能是该病新的表型特征。

主要发现

  • 极端胰岛素抵抗儿童甲状腺结节患病率为16.7%(5/30),显著高于已发表儿童患病率2%(64/3202)。
  • 脂肪营养不良与INSR突变之间甲状腺结节患病率无差异。
  • INSR纯合突变者体表面积校正甲状腺体积为10.4 ± 5.1 cm2,大于杂合突变者的3.9 ± 1.5 cm2和脂肪营养不良者的6.2 ± 3.4 cm2。
  • 3例脂肪营养不良和1例INSR杂合突变患者发现甲状腺乳头状癌(PTC)。
  • 美曲普汀治疗与未治疗患者的甲状腺超声特征无差异。

临床怎么用

  • 对极端胰岛素抵抗综合征患儿应关注甲状腺结构异常,必要时行甲状腺超声筛查。
  • 美曲普汀治疗期间甲状腺超声特征未见差异,但仍需个体化监测。

局限性

  • 需进一步研究确定极端胰岛素抵抗患者甲状腺异常的病因。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Insulin and leptin may increase growth and proliferation of thyroid cells, underlying an association between type 2 diabetes and papillary thyroid cancer (PTC). Patients with extreme insulin resistance due to lipodystrophy or insulin receptor mutations (INSR) are treated with high-dose insulin and recombinant leptin (metreleptin), which may increase the risk of thyroid neoplasia. OBJECTIVE: The aim of this study was to analyze thyroid structural abnormalities in patients with lipodystrophy and INSR mutations and to assess whether insulin, IGF-1, and metreleptin therapy contribute to the thyroid growth and neoplasia in this population. DESIGN: Thyroid ultrasound characteristics were analyzed in 81 patients with lipodystrophy and 11 with INSR (5 homozygous; 6 heterozygous). Sixty patients were taking metreleptin. RESULTS: The prevalence of thyroid nodules in children with extreme insulin resistance (5 of 30, 16.7%) was significantly higher than published prevalence for children (64 of 3202; 2%), with no difference between lipodystrophy and INSR. Body surface area-adjusted thyroid volume was larger in INSR homozygotes vs heterozygotes or lipodystrophy (10.4 ± 5.1, 3.9 ± 1.5, and 6.2 ± 3.4 cm2, respectively. Three patients with lipodystrophy and one INSR heterozygote had PTC. There were no differences in thyroid ultrasound features in patients treated vs not treated with metreleptin. CONCLUSION: Children with extreme insulin resistance had a high prevalence of thyroid nodules, which were not associated with metreleptin treatment. Patients with homozygous INSR mutation had thyromegaly, which may be a novel phenotypic feature of this disease. Further studies are needed to determine the etiology of thyroid abnormalities in patients with extreme insulin resistance.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Kushchayeva YS, Kushchayev SV, Startzell M, et al. Thyroid Abnormalities in Patients With Extreme Insulin Resistance Syndromes. J Clin Endocrinol Metab. 2019. PMID: 30657911. doi:10.1210/jc.2018-02289

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。